Group 1: Company Overview and Product Development - The company focuses on innovative drugs primarily in cardiovascular, urology, oncology, and respiratory systems, with 6 innovative drugs in development, including 1 in Phase III, 2 in Phase I, and 3 in preclinical research [2] - The product Aipulete has shown strong market performance, with projected sales of 119 million tablets in 2024, representing a 30.28% increase from the previous year [2] - The company emphasizes innovation-driven development strategies, enhancing R&D platforms, increasing investment in technology innovation, and promoting digital transformation and sustainable development [2] Group 2: Export Strategy and International Development - The company primarily exports raw materials to markets in North America, Eastern Europe, Southeast Asia, South America, and Oceania [3] - The company established Unioncle Pharma LLC in the U.S. in 2023 to facilitate international collaboration and accelerate the internationalization of its R&D products [3] - The company is actively seeking opportunities for its newly developed raw materials through various channels to enhance its global presence [3] Group 3: Strategic Acquisitions - The company acquired Longyi Pharmaceutical to strengthen its market presence in Southwest China, aiming to create a dual-core driving pattern with its headquarters in the Yangtze River Delta [4] - Longyi Pharmaceutical has a dense distribution network and advantages in the outpatient market, which will accelerate the regional penetration of the company's existing products [4] - The company's national sales system will provide Longyi Pharmaceutical with more upstream pharmaceutical cooperation resources, expanding its wholesale categories [4]

三、同类药品的市场状况 证券代码：600062 证券简称：华润双鹤 公告编号：临 2025-016 华润双鹤药业股份有限公司 关于全资孙公司秦皇岛紫竹药业有限公司 左炔诺孕酮原料药获得WHO的CPQ证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 近日，华润双鹤药业股份有限公司(以下简称"公司")全资孙公司 秦皇岛紫竹药业有限公司(以下简称"秦皇岛紫竹")收到了世界卫生组 织(World Health Organization 以下简称"WHO")签发的左炔诺孕酮原 料 药 ( 微 粉 ) 预 资 质 认 证 证 书 (Confirmation of WHO Active Pharmaceutical Ingredient Prequalification，以下简称"CPQ 证书")。 现将相关情况公告如下： 一、批件主要内容 | 名称 | 通用名称：左炔诺孕酮(微粉) | | --- | --- | | | 英文名/拉丁名：Levonorgestrel(micronized) | | 类别 原料药 | | | W ...